| Identification | Back Directory | [Name]
(2R,4S)-4-(2H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid | [CAS]
125546-04-5 | [Synonyms]
LY 233053
FAAVTENFCLADRE-RITPCOANSA-N
(2R,4S)-4-(2H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid
(2R*,4S*)-4-(1H-Tetrazol-5-ylmethyl)-2-piperidinecarboxylicacid
2-Piperidinecarboxylic acid, 4-(2H-tetrazol-5-ylmethyl)-, (2R,4S)-rel- | [Molecular Formula]
C8H13N5O2 | [MDL Number]
MFCD00885777 | [MOL File]
125546-04-5.mol | [Molecular Weight]
211.22 |
| Hazard Information | Back Directory | [Uses]
LY 233053 is an NMDA receptor antagonist. | [Biological Activity]
Competitive NMDA receptor antagonist (IC 50 = 7 nM) that displays no affinity for AMPA or kainate receptors at a concentration of 10 μ M. Inhibits NMDA-induced neuronal degeneration and protects from NMDA-induced convulsions in neonatal rats. | [in vivo]
LY 233053 (0.5 and 5 mg/kg) has no effects on the electroconvulsive threshold but potentiated the anticonvulsant action of all antiepileptics studied[1].
LY 233053 (5 mg/kg) with carbamazepine, diphenylhydantoin, or phenobarbital provides a 50% protection against maximal electroshock, and results in the impairment of long-term memory[1].
LY233053 (intravenous bolus injection;100 mg/kg; administered 5, 30, or 60 minutes after reversible spinal cord ischemia) is effective in limiting ischemic damage, but protection is lost if therapy is not initiated within 60 minutes of injury in New zealand White rabbits[2]. | [IC 50]
NMDA Receptor |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|